SB4 in the Era of Biosimilars: Clinical Data and Real-World Experience

SB4 in the Era of Biosimilars: Clinical Data and Real-World Experience

A biosimilar is a biological medicinal product that is highly similar to an already authorized original biological medicinal product. The introduction of biosimilars may allow for a reduction in health care costs, due to discount pricing. Current clinical studies and real-world data suggest that the...

Full description

Bibliographic Details
Main Authors:	Shing T. Law, Peter C. Taylor
Format:	Article
Language:	English
Published:	PCO Convin S.A. 2019-01-01
Series:	Mediterranean Journal of Rheumatology
Subjects:	biosimilar anti-tnf sb4; rheumatoid arthritis psoriatic arthritis ankylosing spondylitis real-world data
Online Access:	https://www.mjrheum.org/assets/files/792/file170_679.pdf

Similar Items

Persistence to subcutaneous biological agents in Hungarian patients treated for inflammatory arthritis
by: Takacs P, et al.
Published: (2019-01-01)

The interchangeability of original tumor necrosis factor- α inhibitors and biosimilars in rheumatology: experience in replacing original infliximab with Flammagis for ankylosing spondylitis
by: Yu. V. Muravyev, et al.
Published: (2020-05-01)

Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
by: M. Rossini, et al.
Published: (2015-03-01)

The Portuguese Society of Rheumatology position paper on the use of biosimilars - 2017 update
by: Filipe C. Araújo, et al.
Published: (2017-07-01)

IL-33 Gene Polymorphisms as Potential Biomarkers of Disease Susceptibility and Response to TNF Inhibitors in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Patients
by: Milena Iwaszko, et al.
Published: (2021-06-01)

Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register
by: Paloma Vela, et al.
Published: (2020-06-01)

Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line
by: Svedbom A, et al.
Published: (2017-01-01)

Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
by: Vandana Bhushan, et al.
Published: (2021-09-01)

Bone phenotypes in rheumatology – there is more to bone than just bone
by: Christian S. Thudium, et al.
Published: (2020-11-01)

Comorbidities in inflammatory joint and spine diseases in XXI century
by: I Z Gaydukova, et al.
Published: (2018-12-01)

Association between use of disease-modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis/psoriatic arthritis: a nationwide, population-based cohort study of 84,989 patients
by: Chen HH, et al.
Published: (2017-05-01)

Evaluation of the safety and satisfaction of rheumatic patients with accelerated infliximab infusion
by: Jozélio Freire de Carvalho, et al.
Published: (2018-08-01)

Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study
by: Joshua L. Lee, et al.
Published: (2018-08-01)

IL-23 and Th17 Disease in Inflammatory Arthritis
by: Toru Yago, et al.
Published: (2017-08-01)

Association Between Nursing Support Levels and Effectiveness of Golimumab in the Management of Patients with Rheumatologic Diseases
by: Hermine Leroi, et al.
Published: (2020-05-01)

Intestinal microsporidiosis: a hidden risk in rheumatic disease patients undergoing anti-tumor necrosis factor therapy combined with disease-modifying anti-rheumatic drugs?
by: Nadia Emi Aikawa, et al.
Published: (2011-01-01)

A Three Year Retrospective Analysis Of Anti-Tnf Treatment Outcomes In Rheumatoid Arthritis And Ankylosing Spondylitis Patients
by: Seyfettin Üstünsoy, et al.
Published: (2020-09-01)

Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel
by: Tim A. Kanters, et al.
Published: (2017-05-01)

Switching patients with inflammatory arthritis from Etanercept (Enbrel®) to the biosimilar drug, SB4 (Benepali®): A single-centre retrospective observational study in the UK and a review of the literature
by: Madenidou Anastasia-Vasiliki, et al.
Published: (2019-01-01)

Disease Differentiation and Monitoring of Anti-TNF Treatment in Rheumatoid Arthritis and Spondyloarthropathies
by: Katarzyna Bogunia-Kubik, et al.
Published: (2021-07-01)

Use of antidepressants and benzodiazepine-related hypnotics before and after initiation of TNF-α inhibitors or non-biological systemic treatment in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
by: Philip Brenner, et al.
Published: (2020-02-01)

Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis
by: Santhi Mantravadi, et al.
Published: (2020-09-01)

Ankylosing spondylitis and psoriatic arthritis: clinical and economic consequences of the use of etanercept
by: Viola Sacchi, et al.
Published: (2010-06-01)

Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis
by: Josef S. Smolen, et al.
Published: (2020-08-01)

Treatment Pattern Analysis and Health-care Resource Consumption on Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Biological Drugs in a Northern Italian Region
by: Perrone V, et al.
Published: (2020-06-01)

Etanercept biosimilar associated with Guillain-Barré syndrome: insights from a case
by: V. Shobha, et al.
Published: (2019-07-01)

Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases
by: Laura Cometi, et al.
Published: (2020-05-01)

Systemic Inflammatory Response and Atherosclerosis: The Paradigm of Chronic Inflammatory Rheumatic Diseases
by: Aikaterini Arida, et al.
Published: (2018-06-01)

Classical and paradoxical effects of TNF-α on bone homeostasis
by: Bilal eOsta, et al.
Published: (2014-02-01)

Body Mass Index and Disease Activity in Chronic Inflammatory Rheumatic Diseases: Results of the Cardiovascular in Rheumatology (Carma) Project
by: Jesús A. Valero-Jaimes, et al.
Published: (2021-01-01)

Adherence to biological therapies in patients with chronic inflammatory arthropathies
by: Noemí Martínez-López de Castro, et al.
Published: (2019-07-01)

Treatment persistence of subcutaneous TNF inhibitors among Australian patients with immune-mediated rheumatic disease (IMRD)
by: Acar M, et al.
Published: (2018-11-01)

The troubling liaison between cancer and metabolic syndrome in chronic inflammatory rheumatic diseases
by: Giovanni Cioffi, et al.
Published: (2021-03-01)

Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
by: Sanjiv Kapoor, et al.
Published: (2019-06-01)

Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study
by: Muhammad Haroon, et al.
Published: (2018-04-01)

BIOSIMILARS IN RHEUMATOLOGY
by: E. L. Nasonov
Published: (2017-01-01)

Golimumab for Treating Chronic Inflammatory Joint Diseases in the Adult Population: Clinical Efficacy and Tolerability
by: Natal’ya N. Chichasova
Published: (2019-01-01)

Demographic, clinical and radiological characteristics of seronegative spondyloarthritis Egyptian patients: A rheumatology clinic experience in Mansoura
by: Adel Abdelsalam, et al.
Published: (2017-04-01)

Secukinumab for ankylosing spondylitis and psoriatic arthritis
by: Lubrano E, et al.
Published: (2016-10-01)

Diagnosis of spondyloarthritis: should we need new criteria?
by: I. Z. Gaidukova, et al.
Published: (2015-03-01)